Michael Mauro, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, shares the key topics that were shared at the session on pediatrics, biomarkers, and COVID-19 that took place at this year’s ESH CML meeting, including unmet needs in pediatric chronic myeloid leukemia (CML), deciding between first and second-generation tyrosine kinase inhibitors (TKIs), and data on COVID-19 vaccination response in patients with CML. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Research funding: Novartis, Bristol Myers Squibb, Sun Pharma/Sparc, Takeda; consultancy: Novartis, Bristol Myers Squibb, Takeda, Pfizer.